secwatch.observer — SEC 8-K summary
======================================

Issuer:     CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK:        0001369568
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0001193125-23-207423
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Catalyst Q2 revenue $99.6M, GAAP EPS $0.33 (vs $0.20), raises FY2023 guide to $380M-$390M
--------------------------------------------------------------------------------

- Q2 net product revenue $99.5M: FIRDAPSE $64.9M (+22% YoY); FYCOMPA $34.6M first-time contribution.
- GAAP net income $37.8M, diluted EPS $0.33; Non-GAAP net income $60.4M, diluted EPS $0.53.
- Raised FY2023 total revenue guidance to $380M-$390M.
- Closed acquisition of North American vamorolone license for $75M in July; $15M Santhera equity investment and $10M Ruzurgi installment paid post-Q2.
- Submitted sNDA for FIRDAPSE to increase maximum indicated dose to 100 mg/day.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1369568/000119312523207423/0001193125-23-207423-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1369568/000119312523207423/d497533d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-207423

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer